Guardant Health Announces Executive Changes and Board Appointments

TL;DR

Guardant Health's CMO is out, two new directors are in, and exec pay details are out.

AI Summary

Guardant Health, Inc. announced on March 18, 2024, the departure of its Chief Medical Officer, Dr. Amirali Talasaz, effective March 15, 2024. The company also reported the election of two new directors, Dr. Jonathan M. Lim and Ms. Sarah E. Emrey, to its Board of Directors. Additionally, the company disclosed compensatory arrangements for certain officers.

Why It Matters

This filing indicates significant leadership changes within Guardant Health, including the departure of a key executive and the addition of new board members, which could signal strategic shifts or governance updates.

Risk Assessment

Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding company strategy and future performance.

Key Players & Entities

• Guardant Health, Inc. (company) — Registrant
• Dr. Amirali Talasaz (person) — Departing Chief Medical Officer
• Dr. Jonathan M. Lim (person) — Newly Elected Director
• Ms. Sarah E. Emrey (person) — Newly Elected Director
• March 18, 2024 (date) — Report Date
• March 15, 2024 (date) — Effective Date of Departure

FAQ

From the Filing

0001193125-24-075436.txt : 20240322 0001193125-24-075436.hdr.sgml : 20240322 20240322171005 ACCESSION NUMBER: 0001193125-24-075436 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240318 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 24776150 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d56043d8k.htm 8-K 8-K false 0001576280 0001576280 2024-03-18 2024-03-18     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18, 2024, the independent directors of the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) approved entering into a letter agreement (the “Letter Agreement”) with Helmy Eltoukhy, the Company’s Chairman and Co-Chief Executive Officer and AmirAli Talasaz, the Company’s Co-Chief Executive Officer (the “co-CEOs”). The Letter Agreements amend and restate the pri